Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: Prevention by α-tocopherol?

Molecular and Cellular Biochemistry

Volumn 188, Issue 1-2, 1998, Pages 103-111

  Rösen, Peter ^a,b   Du, Xueliang ^a   Tschöpe, Diethelm ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Diabetesforschungsinstitut   (Germany)

Author keywords

Diabetes; Endothelium; Lipid peroxidation; Myocardium; Nitric oxide; Oxygen derived radicals; Transcription factor NF B; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID HYDROPEROXIDE; NITRIC OXIDE; OXYGEN RADICAL; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VASODILATOR AGENT;

AUTOOXIDATION; CONFERENCE PAPER; DIABETES MELLITUS; GLYCATION; HUMAN; METABOLIC REGULATION; MYOCARDIAL DISEASE; OXIDATIVE STRESS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOMYOPATHIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; FREE RADICALS; HUMANS; REACTIVE OXYGEN SPECIES; VITAMIN E;

EID: 0031786420     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006876607566     Document Type: Conference Paper

References (64)

1. Schernthaner G: Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diab Res Clin Pract 31(suppl): S3-S14,1996
2. Laakso M, Lehtoo S, Penttilä I, Pyörälä K: Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88: 1421-1430,1993
3. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors. The Framingham Study. Circulation 1: 8-13,1979
4. Pyörälä K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: An epidemiological view. Diabetes Metab Rev 3: 463-524,1987
5. Uusitupa MIJ, Mustonen JN, Airaksinen KEJ: Diabetic heart muscle disease. Ann Med 22: 377-386,1990
6. Crepaldi G, Nosadini R: Diabetic cardiopathy: Is it a real entity. Diabetes Metab Rev 4: 273-288,1988
7. Rösen P, Pogatsa G, Tschöpe D, Addicks K, Reinauer H: Diabetische Kardiopathie: Pathophysiologische Konzepte and therapeutische Ansätze. Klin Wochenschr 69(suppl XXIX): 3 15,1992
8. Regan TJ, Lyons MM, Ahmed S, Levinson G, Oldewurtel H, Ahmed M, Haider B: Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60: 885-899,1977
9. Hamby R, Zoneraich S, Sherman S. Diabetic cardiomyopathy. JAMA 229: 1749-1754,1974
10. Shapiro LM, Leatterdale BA, Mackinnon J, Fletcher RF: Left ventricular function in diabetes mellitus. Br Heart J 45: 129-132,1981
11. The Diabetes Control and Complication Trial Research. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986,1993
12. The Diabetes Control and Complication Trial Research. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complication Trial. Kidney Int 47: 1703-1720,1995
13. Rösen P, Ballhausen T, Bloch W, Addicks K. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: Influence of tocopherol as antioxidant. Diabetologia 8: 1157-1168,1995
14. Giugliano D, Ceriello A, Paolisso G: Diabetes mellitus, hypertension, and cardiovascular disease: Which role for oxidative stress? Metabolism 44: 363-368,1995
15. Baynes JE: Role of oxidative stress in the development of complications in diabetes. Diabetes 40: 405-412,1991
16. Nourooz-Zadeh J, Tajaddini-Sarmadi J, McCarthy S, Betteridge DJ, Wolff SP: Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes 44: 1054-1058,1995
17. Nourooz-Zadeh J, Halliwell B, Tritschler H, Betteridge DJ : Decreased lipid standardised plasma α-tocopherol in non-insulin-dependent diabetes mellitus. Diabetes & Stoffw 6(suppl 2): 20-23,1997
18. Nishigaka I, Hagihara M, Tsunekawa H, Maseki M, Yagi K: Lipid peroxide levels of serum lipoprotein fractions of diabetic patients. Biochem Med 25: 373-378,1981
19. Bellomo G, Maggi E, Polli M, Agosta FG, Bollati P, Finardi G: Autoantibodies against oxidatively modified low density lipoproteins in NIDDM. Diabetes 44: 60-66,1995
20. Rösen P, Tchöpe D. Vitamin E and Diabetes. Fat Sci Technol 11: 25-431,1991
21. Gopaul NK, Anggard EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J: Plasma 8-epi-PGF2a levels are elevated in individuals with NIDDM. FEBS Lett 368: 225-229,1995
22. Davi G, Mezzetti A, Vitacolonna E, Costantini F, Pennese E, Falco A, Ciabattoni G, Patrono C, Consoli A: In vivo formation of 8-epi-prostaglandin F2α in diabetes mellitus. Effects of tight control and vitamin E supplementation. Diabetes 46(suppl 1): 113A,1997
23. Jain SK, McVie R, Duett J, Herbst JJ: Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 38: 1539-1543,1989
24. Bellomo G, Maggi E, Palladini G, Perugini, Seccia M: Oxidation of low density lipoproteins and vitamin Ii status in non insulin dependent diabetes mellitus (NIDDM). Diabetes & Stoffw 6(suppl 2): 29-33,1997
25. Leonhardt W, Hanefeld M, Lattke P, Jaroß W: Vitamin E Mangel und Oxidierbarkeit der Low-Density-Lipoproteine bei Typ I und Typ II Diabetes: Einfluß der Qualität der Stoffwechselkontrolle. Diabetes & Stoffw 6(suppl 2): 24-28,1997
26. Reavan PD, Herold DA, Barnett J, Edelmann S: Effects of vitamin E on susceptibility of LDL and LDL subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care 18: 807-816,1995
27. Simon-Schnass I, Rosak Ch, Tritschler HJ, Rösen P: Alpha-Tocopherolaufnahme und zufuhr bei Typ II Diabetikern. Diabetes & Stoffw 6(suppl 2): 16-19,1997
28. Karpen CW, Cataland S, D'Orisiso D, Panaganamal RV: Production of 12-HETE and vitamin Ii status in platelets of type 1 diabetes subjects. Diabetes 34: 526-531
29. 2, in human umbilical vein endothelial cells cultured in high glucose. Diabetologia 37: 264-269,1994
30. Maxwell SRJ, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GHG, Jones AF, Barnett AH: Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27: 484-490,1997
31. Minor RL, Myers PR, Guerra R, Bates JN, Harrison DG: Diet-induced atherosclerosis increases the release of vascular relaxing factor. J Clin Invest 86: 2109-2116,1990
32. Keaney JF, Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, Loscalzo J, Vita JA: Low dose α-tocopherol improves and high dose α-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 93: 844-851,1994
33. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546-2551,1993
34. 1 high pro insulin and glucose in human umbilical vein endothelial cells is mediated by reactive oxygen species. Diabetologia 41: 249-256,1998
35. 2+/EDRF signalling are due to generation of superoxide anions. Diabetes 45: 1386-1395,1996
36. Hunt JA, Smith CCT, Wolff SP. Autoxidativc glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39: 1420-1424,1990
37. Giardino I, Edelsteine D, Brownlee M: BCL-2 expression or antioxidants prevent hyperglycemia induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 97: 1422-1428,1996
38. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897,1994
39. Lyons TJ: Oxidised low density lipoproteins: A role in the pathogenesis of atherosclerosis in diabetes? Diabetes Med 8: 411-419,1991
40. Dietrich D, Skepec J, Diederich A, Dai FX: Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: Role of free radicals. Am J Physiol 266: H1153-H1161,1994
41. Pieper GM, Gross GJ: Oxygen free radicals abolish endothelium dependent relaxation in diabetic rat aorta. Am J Phyiol 255: H825-H833,1988
42. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radical Biol Med 16: 383-391,1994
43. Cohen RA: Dysfunction of vascular endothelium in diabetes mellitus. Circulation 87(suppl V): V67-V76,1993
44. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR: Impairment of coronary vascular reserve and Ach induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 42: 1017-1025,1993
45. Jessup W: Oxidised lipoproteins and nitric oxide. Curr Opin Lipidology 7: 274-280,1996
46. Brown AJ: Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidology 7: U162-U167,1996
47. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D: Activated transcription factor nuclear factor-kappa B is present in atherosclerotic lesion. J Clin Invest 97: 1715-1722,1996
48. Schmidt HH, Walter U: NO at work. Cell 78: 919-925,1994
49. Rösen P, Hönack C, Müssig K, Bloch W, Addicks K: Influence of AT1 receptor inhibition on cardiac function and structure of diabetic rats. In: NS Dhalla, P Zahradka, IMC Dixon, RE Beamish (eds). Angiotensin II Receptor Blockade: Physiological and Clinical Implications. Kluwer Academic Press, Boston, (in press)
50. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809,1993
51. Gey KF, Puska P, Jordan P, Moser UK: Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 53: 326S-334S,1991
52. Riemersma RA, Oliver M, Elton RA, Alfthan G, Vartiainen E, Salo M, Rubba P, Mancini M, Georgi H, Vuilleumier JP et al.: Plasma antioxidants and coronary heart disease: Vitamins C and F, and selenium. Eur J Clin Nutr 44: 143-150,1990
53. Stampfer MJ, Hennekens CH, Marrison JE, Colditz GA, Rosner B, Willet WC: Vitamin E consumption and the risk of coronary disease in woman. N Engl J Med 328: 1444-1449,1993
54. Rimm EB, Stampfer MJ, Ascherio A, Giovannuci E, Colditz GA, Willet WC: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328: 1450-1456,1993
55. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM: Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 334: 1156-1162,1996
56. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029-1035,1994
57. Blot WI, Li IY, Taylor PR et al.: Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population. J Natl Cancer Inst 85: 1483-1492,1993
58. Haeger K: Long-time treatment of intermittent claudication with vitamin E. Am J Clin Nutr 27: 1179-1181,1974
59. Livingston PD, Jones C: Treatment of intermittent claudication with vitamin E. Lancet 2: 602-604,1958
60. Williams HTG, Fenna D, MacBeth RA: Alpha-tocopherol in the treatment of intermittent claudication. Surg Gynccol Obstet 132: 662-666,1971
61. Stephens Ng, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson M, Brown MI: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347: 781-786,1996
62. Hodis HN, Mack WJ, LaBree L et al.: Serial coronary angiographic evidence that antioxidant vitamin intake reduced progression of coronary artery atherosclerosis. JAMA 273: 1849-1854,1995
63. DeMaio SJ, King SB, Lembo NJ, Roubin GS, Hearn JA, Bhagavan HN, Sgoutas DS: Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Nutr 11: 68-73,1992
64. Traber MG, Packer L: Vitamin E: Beyond antioxidant function. Free Rad Biol Med 19: 227-250,1995